Literature DB >> 19337990

Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model.

Vassilis Aggelis1, Rachel A Craven, Jianhe Peng, Patricia Harnden, David A Cairns, Eamonn R Maher, Robert Tonge, Peter J Selby, Rosamonde E Banks.   

Abstract

The von Hippel-Lindau (VHL) tumour suppressor gene plays a central role in development of clear cell renal cell carcinoma (RCC). Using a cell line pair generated from the VHL-defective RCC cell line UMRC2 by transfection with vector control or VHL (-/+VHL) and stable isotope labelling with amino acids in cell culture (SILAC) followed by enrichment of plasma membrane proteins by cell surface biotinylation/avidin-affinity chromatography and analysis by GeLC-MS/MS, VHL-associated changes in plasma membrane proteins were analysed. Comparative analysis of -/+VHL cells identified 19 differentially expressed proteins which were confirmed by reciprocal SILAC labelling. These included several proteins previously reported to be VHL targets, such as transferrin receptor 1 and the alpha 3 and beta1 integrin subunits and novel findings including upregulation of CD166 and CD147 in VHL-defective cells. Western blotting confirmed these changes and also revealed VHL-dependent alterations in protein form for CD147 and CD166, which in the case of CD166 was shown to be due to differential glycosylation. Analysis of patient-matched normal and malignant renal tissues confirmed these differences were also present in vivo in a subset of clear cell RCCs. These results illustrate the potential of this approach for identifying VHL-dependent proteins that may be important in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19337990     DOI: 10.1002/pmic.200800756

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  14 in total

Review 1.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

2.  Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro.

Authors:  Craig Gedye; Tracy Cardwell; Nektaria Dimopoulos; Bee Shin Tan; Heather Jackson; Suzanne Svobodová; Matthew Anaka; Andreas Behren; Christopher Maher; Oliver Hofmann; Winston Hide; Otavia Caballero; Ian D Davis; Jonathan Cebon
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

Review 3.  Plasma membrane proteomics and its application in clinical cancer biomarker discovery.

Authors:  Rikke Leth-Larsen; Rikke R Lund; Henrik J Ditzel
Journal:  Mol Cell Proteomics       Date:  2010-04-08       Impact factor: 5.911

Review 4.  [Identification of VHL-associated changes in clear cell renal carcinoma: the application of combined genome and expression analyses].

Authors:  G Boysen; B Wollscheid; D Bausch-Fluck; P Schraml; H Moch
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

5.  The secreted and surface proteomes of the adult stage of the carcinogenic human liver fluke Opisthorchis viverrini.

Authors:  Jason Mulvenna; Banchob Sripa; Paul J Brindley; Jeffrey Gorman; Malcolm K Jones; Michelle L Colgrave; Alun Jones; Sujeevi Nawaratna; Thewarach Laha; Sutas Suttiprapa; Michael J Smout; Alex Loukas
Journal:  Proteomics       Date:  2010-03       Impact factor: 3.984

6.  A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses.

Authors:  Matthew P Welberry Smith; Steven L Wood; Alexandre Zougman; Jenny T C Ho; Jianhe Peng; David Jackson; David A Cairns; Andrew J P Lewington; Peter J Selby; Rosamonde E Banks
Journal:  Proteomics       Date:  2011-05-05       Impact factor: 3.984

7.  Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma.

Authors:  Zhigang Xie; Jayantha Gunaratne; Lip Lee Cheong; Shaw Cheng Liu; Tze Loong Koh; Gaofeng Huang; Walter P Blackstock; Wee Joo Chng
Journal:  Oncotarget       Date:  2013-07

8.  Expression and Role of CD166 in the Chronic Kidney Disease.

Authors:  Yan Sun; Yiping Wang; Qi Cao; Hong Yu; Dong Zheng; Ya Wang; David C H Harris
Journal:  Iran J Pediatr       Date:  2015-10-06       Impact factor: 0.364

9.  State of the art in tumor antigen and biomarker discovery.

Authors:  Klervi Even-Desrumeaux; Daniel Baty; Patrick Chames
Journal:  Cancers (Basel)       Date:  2011-06-09       Impact factor: 6.639

10.  VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer.

Authors:  Vassilis Aggelis; Rachel A Craven; Jianhe Peng; Patricia Harnden; Lana Schaffer; Gilberto E Hernandez; Steven R Head; Eamonn R Maher; Robert Tonge; Peter J Selby; Rosamonde E Banks
Journal:  Int J Oncol       Date:  2013-08-21       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.